These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 14687987

  • 1. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR, Zinzani P, Zaja F, Gentile M, Vegna ML, Stefoni V, Marin L, Fanin R, Baccarani M, Tura S, Mandelli F.
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [Abstract] [Full Text] [Related]

  • 2. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL, Levrero MG, Lauria F, Rondelli D, Zaja F, Russo D, Fanin R, De Rossi G, Mauro FR, Bendandi M, Gozzetti A, Dianzani F, Mandelli F, Tura S.
    Haematologica; 1994 Dec; 79(1):55-60. PubMed ID: 15378949
    [Abstract] [Full Text] [Related]

  • 3. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
    O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ.
    Blood; 1995 Aug 15; 86(4):1298-300. PubMed ID: 7632936
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR, Gentile M, Mancini F, Giannarelli D, Guarini A, De Propriis MS, Cerretti R, Foa R.
    Haematologica; 2002 Jun 20; 87(6):602-8. PubMed ID: 12031916
    [Abstract] [Full Text] [Related]

  • 6. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 01; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 11. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.
    J Clin Oncol; 2010 Apr 10; 28(11):1863-9. PubMed ID: 20212251
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct 14; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 18. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D.
    Cancer; 1997 Jun 01; 79(11):2107-14. PubMed ID: 9179056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.